Abstract: Diabetic vascular complication is a leading cause of end-stage renal failure, acquired blindness, a variety of neuropathies and accelerated atherosclerosis, which could account for disabilities and high mortality rates in patients with diabetes. There is a growing body of evidence to conclude that intensive control of plasma glucose and blood pressure is crucial for effectively reducing diabetic vascular complication. So far, various molecular mechanisms have been proposed to play a role in the development and progression of diabetic vascular complication. In this paper, we review potential therapeutic strategies for the prevention of diabetic vascular complication, especially focusing on the signal transduction pathways activated under diabetes.
INTRODUCTION
Diabetic vascular complication is a leading cause of endstage renal failure, acquired blindness, a variety of neuropathies and accelerated atherosclerosis, which could account for disabilities and high mortality rates in diabetic patients. Indeed, cardiovascular diseases (CVD) account for about 70 % of total mortality, and all manifestations of them such as coronary heart disease, stroke, and peripheral vascular disease are substantially more common in patients with diabetes [Laakso, 1999] . Chronic hyperglycemia is a major initiator of vascular complications of diabetes. Various hyperglycemiainduced metabolic and hemodynamic derangements, including increased advanced glycation end product (AGE) formation, enhanced production of reactive oxygen species (ROS), activation of protein kinase C (PKC), stimulation of the polyol pathway and the renin-angiotensin system (RAS), contribute to the characteristic histopathological changes observed in diabetic vascular complications [Brownlee, 2001] . Two recent large prospective clinical studies, the Diabetes Control and Complications Trial (DCCT) and the United Kigdom Prospective Diabetes Study (UKPDS), have shown that intensive blood glucose or blood pressure (BP) control effectively reduces microvascular complications among patients with diabetes [DCCT Research Group, 1993; UKPDS Group, 1998 ]. However, control of hyperglycemia or high BP to strict levels is often very difficult to maintain in diabetic patients [DCCT Research Group, 1993; UKPDS Group, 1998 ]. Therefore, to develop novel therapeutic strategies that specifically target diabetic vascular complications may be helpful for most patients with diabetes. In this paper, we review potential therapeutic strategies for the prevention of diabetic microvascular complication, especially focusing on the signal transduction pathways activated under diabetes.
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DIABETIC RETINOPATHY (1). Pathophysiology of Diabetic Retinopathy
Diabetic retinopathy is one of the most important microvascular complications in diabetes and is a leading cause of acquired blindness among the people of occupational age. The lesions of diabetic retinopathy can be grouped into those associated with background, preproliferative and proliferative retinopathy.
The earliest histopathological hallmark of diabetic retinopathy is loss of pericytes [Cogan et al. 1961] . In parallel with loss of pericytes, several characteristic changes including thickening of the basement membrane, hyperpermeability, and formation of microaneurysm are observed [Mandarino, 1992; Rank, 1991] . These structural and functional abnormalities are followed by microvascular occlusion in the retinas, which ultimately progresses to proliferative changes associated with neovascularization [Mandarino, 1992; Rank, 1991] . Therefore, it has been postulated that many of these changes are the consequent of the loss of pericytes.
We have previously found that pericytes not only regulate the growth, but also preserve the prostacyclinproducing ability and protect against lipid-peroxide-induced injury of endothelial cells (ECs), thus playing an important role in the maintenance of microvascular homeostasis [Yamagishi et al. 1993a,b] . Therefore, the loss of pericytes could predispose the vessels to angiogenesis, thrombogenesis, and EC injury, leading to full clinical expression of diabetic retinopathy. Further, recently, Hammes et al. investigated the role of capillary coverage with pericytes in early diabetic retinopathy and the contribution to proliferative retinopathy using mice with a single functional allele of platelet-derived growth factor-B (PDGF-B(+/-) mice) [Hammes et al. 2002] . They demonstrated in their studies that retinal capillary coverage with pericytes is crucial for the survival of ECs, particularly under stress conditions such as diabetes, and that pericyte deficiency leads to reduced inhibition of EC proliferation, thus promoting angiogenesis in the retinopathy of prematurity model. These in vitro and in vivo observations provide a basis for understanding why diabetic retinopathy develops consequent to pericyte loss, the earliest histopathological hallmarks of diabetic retinopathy.
(2). Molecular Mechanisms of Diabetic Retinopathy and its Prevention

(i). Involvement of AGEs and their Receptor (RAGE) System
A non-enzymatic reaction between ketones or aldehydes and the amino groups of proteins contributes to the aging of proteins and to pathological complications of diabetes [Dyer et al. 1991; Grandhee and Monnier, 1991] . Under hyperglycemic conditions in diabetes, this process begins with the conversion of reversible Schiff base adducts, and then to more stable, covalently-bound Amadori rearrangement products. Over a course of days to weeks, these early glycation products undergo further reactions and rearrangements to become irreversible crossed-linked, fluorescent protein derivatives termed AGEs.
Retinal pericytes accumulate AGEs during diabetes, which would be expected to have a detrimental influence on pericyte survival and function [Stitt et al. 1997] . AGEs are toxic to retinal pericytes in vitro; we have found that AGEs not only induce growth retardation and apoptotic cell death of, but also exert an immediate toxicity to, cultured retinal pericytes Yamagishi et al. 2002a] . Antisense DNA complementary mRNA coding for a receptor for AGEs (RAGE) reversed the AGE-induced decrease in viable cell number of pericytes, while overexpression of RAGE potentiated the deleterious effects of AGEs. These results suggest that the AGE effects on pericytes could be mediated through the interactions with RAGE.
We found that reactive oxygen species (ROS) generation elicited by the AGE-RAGE interaction mediated these deleterious effects of AGEs . Moreover, AGEs up-regulated RAGE mRNA levels in pericytes through the intracellular ROS generation as well [Tanaka et al. 2001] . Therefore, these positive feedback loops transduce the AGE signals, thereby further exacerbating the cytopathic effects of AGEs on pericytes. With regard to a source of ROS generation elicited by AGEs, we have recently found that beraprost sodium, a prostacyclin analogue, or forskolin, an activator of adenylate cyclase, protects against the AGE-induced pericyte apoptosis by suppressing ROS generation and subsequent RAGE overexpression [Yamagishi et al. 2002c] . Since cyclic AMP elevating agents were known to block ROS generation in neutrophils by inhibiting reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity [Otonello et al. 1995] , NADPH oxidase might be a source of ROS production elicited by AGEs and also be a target of beraprost sodium.
Pericyte dysfunction has been considered one of the characteristic changes of early phase of diabetic retinopathy. AGEs act on pericytes to stimulate vascular endothelial growth factor (VEGF) expression both in vitro and in vivo Lu et al. 1998 ]. VEGF is a specific mitogen to ECs, also known as vascular permeability factor, and is generally thought to be involved in the pathogenesis of proliferative diabetic retinopathy. Indeed, some clinical observations have demonstrated that VEGF level in ocular fluid is positively correlated with the activity of neovascularization in diabetic retinopathy [Adamis et al. 1994; Aiello et al. 1994] . Recently, VEGF level was also found to be associated with the breakdown of the bloodretinal barrier, thus being involved in retinal hyperpermeability in background retinopathy [Murata et al. 1995] . These observations suggest that AGEs might be involved in the development of early diabetic retinopathy by inducing VEGF expression in pericytes as well.
Angiopoietin (ang)-Tie receptor interaction plays an important role in both physiological and pathological angiogenesis as well [Folkman and D'Amore, 1996] . Engagement of tie-2 by ang-1 has been known to promote recruitment of pericytes, thereby supporting the establishment and maintenance of vascular integrity; while ang-2 is a naturally occurring antagonist of ang-1, and induces the loosening of contacts between ECs and pericytes [Maisonpierre et al. 1997; Benjamin et al. 1998 ]. AGEs increase a ratio of ang-2 to ang-1 mRNA level and simultaneously up-regulate VEGF mRNA levels in microvascular ECs [Okamoto et al. 2002a] . A plastic window for blood vessel remodeling is defined by pericyte coverage of the preformed endothelial network [Benjamin et al. 1998 ]. Therefore, the AGE-induced pericyte apoptosis and increased ratio of ang-2/ang-1 in ECs could disrupt the pericyte-EC interactions, thus promoting angiogeneis by acting in concert with VEGF.
There has been increasing interest in the role of inflammatory reaction in diabetic retinopathy [Schroder et al. 1991] . AGEs are implicated in the process of vascular inflammation as well. Indeed, AGEs have been recently shown to increase leukocyte adhesion to cultured retinal microvascular ECs by inducing intracellular cell adhesion molecule-1 (ICAM-1) expression [Moore et al. 2003 ]. This phenomenon is also apparent in non-diabetic mice infused with preformed AGEs, which results in significant leukostasis and blood-retinal barrier dysfunction in these mice [Moore et al. 2003] . Recently, retinal VEGF has been found to induce ICAM-1 expression, thus leading to leukostasis and breakdown of blood-retinal barrier in vivo [Lu et al. 1999; Joussen et al. 2002] . It is not known at present whether the AGE-elicited pro-inflammation is modulated by blockage of VEGF. Further, AGEs also induce monocyte chemoattractant protein-1 (MCP-1) in microvascular ECs through intracellular ROS generation ]. Since the levels of MCP-1 in vitreous fluids are correlated with the severity of proliferative diabetic retinopathy [Mitamura et al. 2000] , AGEs would be one of the key pro-inflammatory factors for progression of diabetic retinopathy.
Microthrombosis formation contributes to capillary obliteration and retinal ischemia, thus being involved in the progression of diabetic retinopathy [Boeri et al. 2001] . AGEs inhibit prostacyclin production and induce plasminogen activator inhibitor-1 (PAI-1) in microvascular ECs through an interaction with RAGE [Yamagishi et al. 1996 [Yamagishi et al. , 1998 ]. These observations suggest that AGE have the ability to cause platelet aggregation and fibrin stabilization, resulting in a predisposition to thrombogenesis and thereby contributing to the promotion of diabetic retinopathy. Retinal ischemia due to microthrombus formation may trigger VEGF expression in retinal cells, thus further promoting diabetic retinopathy [Nomura et al. 1995 , Yamagishi et al. 1999a . Since AGEs decrease the intracellular cyclic AMP concentrations in ECs and cyclic AMP agonists such as beraprost sodium and forskolin reduce the AGE-induced PAI-1 production, cyclic AMP elevating agents may have a therapeutic potential in the treatment of diabetic retinopathy.
AGEs also directly stimulate growth and tube formation of microvascular ECs, the key steps of angiogenesis [Yamagishi et al. 1997] . The angiogenic activity of AGEs was significantly enhanced in RAGE-overexpressed ECs, while it was completely inhibited by treatment of antisense DNA against RAGE mRNA. The observations suggest that AGEs could elicit angiogenesis through the interaction with RAGE. We found that it was autocrine VEGF production in ECs that mainly mediated the angiogenic activity of AGEs. Although the molecular mechanisms of VEGF overexpression elicited by AGEs are not fully understood, our recent investigation has shown that the AGE-RAGE interaction might increase VEGF gene transcription in microvascular ECs by NADPH oxidase-mediated ROS generation and the subsequent nuclear factor-B (NF-B) activation via Rasmitogen activated protein kinase (MAPK) pathway [Okamoto et al. 2002a,b] .
Compared to the strategy of preventing AGEs formation, the manupulation of the AGE signaling pathways as a therapeutic option in diabetic retinopathy remains much less developed. However, recently, we have found that pigment epithelium-derived factor (PEDF), one of the superfamily of serine protease inhibitors with potent neuronal differentiating activity in human retinoblastoma cells [Tombran-Tink et al. 1991] , inhibits the AGE-induced pericyte apoptosis and EC proliferation and activation through its anti-oxidative properties Inagaki et al. 2003 ]. Since the levels of vitreal PEDF are decreased in angiogenic eye diseases such as proliferative diabetic retinopathy [Spranger et al. 2002] , substitution of PEDF may disrupt inappropriate retinal cell responses to AGEs, thus being a promising strategy for treatment of patients with diabetic retinopathy.
(ii). Cross-Talk Between AGEs and RAS
The local RAS is activated under diabetes [Anderson, 1997] . We have recently found that angiotensin II (AII) stimulates intracellular ROS generation in retinal pericytes through an interaction with type 1 receptor. Further, AII decreased DNA synthesis and simultaneously up-regulated VEGF mRNA levels in pericytes, both of which were blocked by treatment with telmisartan, a newly developed AII type 1 receptor antagonist, or N-acetylcysteine (NAC), an anti-oxidant [Yamagishi et al. 2003a] . These results suggest that AII-type 1 receptor interaction could induce pericyte loss and dysfunction through intracellular ROS generation, thus being involved in diabetic retinopathy. Furthermore, we have very recently found that AII potentiates the deleterious effects of AGEs on pericytes by inducing RAGE protein expression (unpublished data). The observations suggest the functional interaction between the AGE-RAGE system and the RAS in the pathogenesis of pericyte loss and dysfunction in diabetic retinopathy. AII induced the VEGF receptor expression in retinal microvascular ECs. The retinal RAS might also augment the permeability-and angiogenesis-inducing activity of VEGF, thus being involved in the progression of diabetic retinopathy [Otani et al. 1998 ]. In supprot of this, blockade of the RAS by inhibitors of angiotensin converting enzyme or AII type 1 receptor antagonists have recently been found to reduce retinal overexpression of VEGF and hyperpermeability and neovascularization in experimental diabetes [Nagisa et al. 2001; Gilbert et al. 2000] . In the EUCLID Study, the angiotensin converting enzyme inhibitor, lisinopril, reduced the risk of progression of retinopathy by approximately 50%, and also significantly reduced the risk of progression to proliferative retinopathy although retinopathy was not a primary end-point and the study was not sufficiently powered for the eye-related outcomes [Chaturvedi et al. 1998 ].
(iii). Involvement of PKC
PKC is a family of multifunctional isoenzymes, activated by diacylglycerol (DAG), which plays a central role in signal transduction and gene expression of growth factors and cytokines [Idris et al. 2001] . Labeling studies using [
14 C] glucose have demonstrated that the source of glucosederived DAG was from de novo pathway [Xia et al. 1994] . It has been postulated that the DAG-PKC pathway is activated by hyperglycemic-diabetic states in all vascular cells associated with diabetic complications.
PKC activation can directly increase the vascular permeability of albumin and macromolecules, probably by phosphorylating cytoskeletal proteins forming the intracellula r junctions [Lynch et al. 1990] . PKC activation could regulate vascular permeability and angiogenesis via the expression of growth factors such as VEGF as well [Koya and King, 1998 ]. Further, both the mitogenic and permeabilityinducing actions of VEGF are partly mediated by the activation of PKC- [Aiello et al. 1997] . These observations suggest that inhibition of PKC activity could be a potential therapeutic target for diabetic retinopathy. Indeed, an orally active PKC--selective inhibitor, LY333531, was reported to prevent the increases in leukostasis and the decreases in blood flow in the retinas of diabetic rats Nonaka et al. 2000; Abiko et al. 2003] . A recent initial report of multicenter clinical trials did not show effectiveness of LY333531 on diabetic retinopathy progression although the drug was well tolerated in patients with diabetes [Milton et al. 2003 ].
Vitamin E is another type of PKC inhibitor: it can inhibit PKC activity probably by decreasing DAG contents via the activation of DAG kinase . Recently, highdose vitamin E supplementation has been reported to normalize retinal blood flow in patients with type 1 diabetes [Bursell et al. 1999] .
(iv). Involvement of the Polyol Pathway
The polyol pathway consists of two enzymes, aldose reductase (AR) and sorbitol dehydrogenase (SDH); the former is the first enzyme in the polyol pathway, that catalyzes reduction of glucose to sorbitol, while the latter is the second one, that converts sorbitol into fructose using NAD + as a cofactor [Yabe-Nishimura, 1998 ]. The polyol pathway is activated under hyperglycemic conditions, and is considered to play an important role in the development of diabetic neuropathy in addition to other complications [Kinoshita et al.1998 ]. Intracellular sorbitol accumulation and decline in NADPH contents caused by increases in AR flux has been postulated to induce osmotic damage and oxidative stress, respectively. However, in human studies, AR inhibitors have only a partial effect against early phase of diabetic retinopathy [Sorbinil Retinopathy Trial Research Group] . Such negative findings have fueled controversy surrounding the contribution of AR in diabetic retinopathy.
Increased flux through SDH can lead to an increased ratio of nicotinamide adenine dinucleotide (NADH)/NAD that may alter lipid metabolism and increase production of ROS, thus contributing to the development of diabetic microangiopathies (pseudohypoxia hypothesis) [Williamson et al. 1993] . This redox imbalance may be associated with impaired regulation of retinal blood flow in humans with diabetes and in nondiabetic acutely hyperglycemic animals [Enden et al. 1995] . In order to further examine a functional role of SDH in diabetic retinopathy, we studied effects of SDH overexpression on glucose toxicity to cultured retinal pericytes [Amano et al. 2002] . High glucose modestly increased ROS generation, decreased DNA synthesis and upregulated VEGF mRNA levels in retinal pericytes. SDH overexpression was found to significantly stimulate ROS generation in high glucose-exposed pericytes, and subsequently potentiate the cytopathic effects of glucose. An antioxidant NAC, completely prevented these deleterious effects of SDH overexpression on pericytes. Further, blockade of the polyol pathway was found to significantly prevent vascular hyperpermeability, the characteristic changes of the early phase of diabetic retinopathy, in streptozotocin-induced diabetic rats. These observations suggest that SDH-mediated conversion of sorbitol into fructose and the resultant ROS generation may play a role in the pathogenesis of diabetic retinopathy. Since fructose is a stronger glycating agent than glucose, intracellular AGEs formation via the SDH pathway might be involved in glucose toxicity to retinal pericytes.
(v). Involvement of Oxidative Stress
There is a growing body of evidence that generation of ROS is increased in diabetes. High glucose concentrations, via various mechanisms such as glucose auto-oxidation, increased production of AGEs, activation of PKC and stimulation of the polyol pathway, enhanced ROS generation [Rosen et al. 2001] . Increased ROS generation has been found to regulate vascular inflammation, altered gene expression of growth factors and cytokines, and platelet and macrophage activation, thus playing a central role in the pathogenesis of diabetic vascular complications [Yamagishi et al. 2001a,b] . Further, we have recently found that high glucose-induced mitochondrial overproduction of superoxide serves as a causal link between elevated glucose and hyperglycemic vascular damage in ECs [Nishikawa et al. 2000] . Normalizing levels of mitochondrial ROS prevent glucose-induced formation of AGEs, activation of PKC, sorbitol accumulation, and NF-B activation. These observations suggest that the three main mechanisms implicated in the pathogenesis of diabetic vascular complications might reflect a single hyperglycemia-induced process, thus providing a novel therapeutic target for diabetic angiopathies. Recently, Hammes and Brownlee et al. have discovered that the lipid-soluble thiamine derivative benfotiamine can inhibit the three major biochemical pathways as well as hyperglycemia-associated NF-B activation [Hammes et al. 2003 ]. They showed that benfotiamine prevented experimental diabetic retinopathy by activating the pentose phosphate pathway enzyme transketolase in the retinas, which converts glyceraldehyde-3-phosphate and fructose-6-phosphate into pentose-5-phosphates and other sugars. Thiamine and benfotiamine therapy is reported to prevent streptozotocin-induced incipient diabetic nephropathy as well [Babaei-Jadidi et al. 2003 ].
DIABETIC NEPHROPATHY (1). Pathophysiology of Diabetic Nephropathy
The earliest clinical evidence for incipient diabetic nephropathy is the development of the persistent microalbuminuria (urinary albumin excretion rate (UAER), 20-200 g/min), which is Albustix-negative. The natural history of diabetic nephropathy differs between type 1 and type 2 patients. If untreated, approximately 80 % of type 1 diabetic patients will develop overt albuminuria (UAER>200 g/min) over a 15-year period. Of these patients, 50 % will develop end-stage renal disease (ESRD) over the ensuring 10 years. In type 2 diabetes, if no treatment is initiated, up to 20-40 % of patients will progress to overt albuminuria and 20 % of those with overt albuminuria will develop ESRD over the next 20 years.
Diabetic nephropathy is a leading cause of ESRD, and accounts for disabilities and the high mortality rate in patients with diabetes. Development of diabetic nephropathy is characterized by glomerular hyperfiltration and thickening of glomerular basement membranes, followed by an expansion of extracellular matrix in mesangial areas and increased UAER. Diabetic nephropathy ultimately progresses to glomerular sclerosis associated with renal dysfunction [Sharma and Ziyadeh, 1995] . Further, it has recently been recognized that changes within tubulointerstitium, including proximal tubular cell atrophy and tubulointerstitial fibrosis, are also important in terms of renal prognosis in diabetic nephropathy [Ziyadeh, 1991] . Such tubular changes have been reported to be the dominant lesion in about one third of patients with type 2 diabetes [Fiorreto et al. 1996 ]. It appears that both metabolic and hemodynamic factors interact to stimulate the expression of cytokines and growth factors in glomeruli and tubules from the diabetic kidney [Cooper et al. 2001] . Evidence has implicated the transforming growth factor-(TGF-) system as a major etiologic agent in the pathogenesis of glomerulosclerosis and tubulointerstitial fibrosis in diabetic nephropathy [Sharma and Ziyadeh, 1995] .
(2). Molecular Mechanisms of Diabetic Nephropathy and its Prevention
(i). Involvement of AGE-RAGE System
AGEs induce apoptotic cell death and VEGF expression in human cultured mesangial cells, as the case in pericytes [Yamagishi et al. 200d] . Mesangial cells occupy a central anatomical position in the glomerulus, playing crucial roles in maintaining structure and function of glomerular capillary tufts [Dworkin et al. 1983] . They actually provide structural support for capillary loops and modulate glomerular filtration by its smooth muscle activity. Therefore, the AGE-induced mesangial apoptosis and dysfuction may contribute in part to glomerular hyperfiltration, an early renal dysfunction in diabetes. Recently, antibodies against VEGF have been found to improve hyperfiltration and albuminuria in experimental diabetes, supproting our speculation [Vries et al. 2001] . Further, we have recently found that AGEs stimulate MCP-1 expression in mesangial cells [Yamagishi et al. 2002d] . Increased MCP-1 expression associated with monocyte infiltration in mesangium has been observed in the early phase of diabetic nephropathy [Banba et al. 2000] . AGE accumulation in glomerulus could also be implicated in the initiation of diabetic nephropathy by promoting the secretion of MCP-1 in mesangial cells.
AGEs formation on extracellular matrix proteins alters both matrix-matrix and cell-matrix interactions, involved in the pathogenesis of diabetic glomerulosclerosis. For example, non-enzymatic glycations of type IV collagen and laminin reduce their ability to interact with negatively charged proteoglycans, increasing vascular permeability to albumin [Silbiger et al. 1993] . Furthermore, AGEs formation on various types of matrix proteins impairs their degradation by matrix metalloproteinases, contributing to basement membrane thickening and mesangial expansion, hallmarks of diabetic nephropathy [Mott et al. 1997] . AGEs formed on the matrix components can trap and covalently cross-link with the extravasated plasma proteins such as lipoproteins, thereby exacerbating diabetic glomerulosclerosis.
AGEs stimulate insulin-like growth factor-I, -II, PDGF and TGF-in mesangial cells, which in turn mediate production of type IV collagen, laminin and fibronectin [Brownlee 1994 ]. AGEs induce TGF-overexpression in both podocytes and proximal tubular cells as well [Yamagishi et al. 2003b] . Recently, Ziyadeh et al. reported that long-term treatment of type 2 diabetic model mice with blocking antibodies against TGF-suppressed excess matrix gene expression, glomerulosclerosis, and prevented the development of renal insufficiency [Ziyadeh et al. 2000] . These observations suggest that AGE-induced TGFexpression plays an important role in the pathogenesis of glomerulosclerosis and tubulointerstitial fibrosis in diabetic nephropathy.
In vivo, the administration of AGE-albumin to normal healthy mice for 4 weeks has been found to induce glomerular hypertrophy with overexpression of type IV collagen, laminin B1 and TGF-genes [Yang et al. 1994] . Furthermore, chronic infusion of AGE-albumin to otherwise healthy rats leads to focal glomerulosclerosis, mesangial expansion, and albuminuria . Recently, RAGE-overexpressing diabetic mice have been found to show progressive glomerulosclerosis with renal dysfunction, compared with diabetic littermates lacking the RAGE transgene [Yamamoto et al. 2001] . AGEs including glycoxidation or lipoxidation products such as N -(carboxymethyl) lysine, pentosidine, malondialdehyde-lysine accumulate in the expanded mesangial matrix and thickened glomerular basement membranes of early diabetic nephropathy, and in nodular lesions of advanced disease, further suggesting the active role of AGEs for diabetic nephropathy [Suzuki et al. 1999] .
(ii). Cross-Talk Between AGEs and RAS
There is a growing body of evidence to suggest that that the RAS plays an important role in the regulation of glomerular hemodynamics and renal expression of cytokines, thus being involved in glomerular hyperfiltration and mesangial expansion in diabetic nephropathy [Gilbert et al. 2003] . Several reports suggest an interaction between AGEs and the RAS in diabetic nephropathy. Angiotensin converting enzyme inhibition reduces the accumulation of renal and serum AGEs, probably via effects on oxidative pathways [Forbes et al. 2002] . Long-term treatment with AII receptor 1 antagonist may exert salutary effects on AGEs levels in the rat remnant kidney model, probably due to improved renal function [Sebekova et al. 1999] . Administration of ramipril, an angiotensin converting enzyme inhibitor, has been recently shown to result in a mild decline of fluorescent noncarboxymethllysine-AGEs and malondialdehyde concentrations in non-diabetic nephropathy patients [Sebekova et al. 2003 ]. In addition, we have very recently found that AGE-RAGE-mediated ROS generation activates TGF--Smad signaling and subsequently induces mesangial cell hypertrophy and fibronectin synthesis by autocrine production of AII [Fukami et al. 2003] . Taken together, these data may provide an important mechanistic link between metabolic and haemodynamic factors in promoting the development and progression of diabetic nephropathy.
(iii). Involvement of PKC
Diabetic glomerular hyperfiltration is likely to be the consequences of hyperglycemia-induced decreases in afferent arteriolar resistance, which could lead to glomerular hypertension [O'Donnell et al. 1988] . Some of the vasoconstrictive actions of AII are mediated by PKC activity [Ruan et al. 1996] . DAG-PKC pathway may enhance the action of AII in glomeruli, thus being involved in early diabetic nephropathy. Further, hyperglycemia-induced PKC activation regulates arachidonic acid release and eicosanoid production by mesangial cells [Williams et al. 1993] . Therefore, increases in vasodilatory prostanoids such as prostaglandin E 2 via PKC activation may also be involved in hyperfiltration in diabetic nephropathy. Haneda et al. provided the evidence that MAPK cascade, an important kinase cascade downstream to PKC, activated cytosolic phospholipaseA 2 by direct phosphorylation of this enzyme, in glomeruli isolated from streptozotocin-induced diabetic rats, thus contributing to the development of diabetic nephropathy [Haneda et al. 1997] .
PKC can increase extracellular matrix production in mesangial cells via TGF-activation while PKC inhibitors prevent the hyperglucemia-induced increase in extracellular matrix and TGF-expression in mesangial cells [Kunisaki et al. 1994] . Recently, AGEs are reported to induce oxidative stress and activate PKC-in neonatal mesangial cells, thus causing changes that may ultimately contribute to phenotypic abnormalities associated with diabetic nephropathy [Scivittaro et al. 2000] . AGE-induced TGF-overexpression in mesangial cells could be mediated by PKC activity.
In animal models of diabetes, including the streptozotocin rat, db/db mouse, and diabetic tranegenic mRen-2 rat models, an orally active PKC-inhibitor LY333531, normalized glomerular hyperfiltration, decreased urinary albumin excretion, and reduced glomerular TGF-and extracellular matrix protein production. As a result, mesangial expansion, glomerulosclerosis and tubulointerstitial fibrosis were significantly prevented with improvement of renal function [Tuttle and Anderson, 2003; .
DIABETIC NEUROPATHY (1). Pathophysiology of Diabetic Neuropathy
Diabetes mellitus is a major cause of peripheral neuropathy, commonly manifested as distal symmetrical polyneuropathy [Vinik et al. 2000] . The epidemiology of diabetic neuropathy is unclear because of inconsistency in defining neuropathy. In a large prospective study of diabetic out-patients, the prevalence rose from 7.5 % at the time of diagnosis of diabetes to 50 % after 25 years [Dyck et al. 1985] . The prevalence after 20 years was over 40 %, but in the other prospective study, it was only half of this value. Diabetic neuropathy is associated with risk factors for other vascular complications such as poor metabolic control, dyslipidemia, hypertension, body mass index, smoking, microalbuminuria and retinopathy [Tesfaye et al. 1996] . However, a report from the Steno type-2 randomized study showed the effectiveness of aggressive risk factor control on retinopathy, nephropathy and autonomic neuropathy, but not peripheral neuropathy [Gaede et al. 1999] .
Both vascular and metabolic factors have been involved in the pathogenesis of diabetic neuropathy. Studies in human and animal models have shown reduced nerve perfusion and endoneurial hypoxia, which might play a role in nerve dysfunction [Young et al. 1992] . Retinopathy-like microvasculature changes including basement membrane thickening and pericyte degeneration have been observed in diabetic neuropathy [Powell et al. 1985] , and arterio-venous shunting contributes to reduced endoneurial perfusion as well [Boulton et al. 1982] . Hyperglycemia, via various metabolic derangements, contributes to the etiology of diabetic neuropathy as well.
(2). Molecular Mechanisms of Diabetic Neuropathy and its Prevention
(i). Involvement of AGE-RAGE
Sural, peroneal, and saphenous nerves of human diabetic subjects contained AGEs in the perineurium, ECs, and pericytes of endoneurial microvessels and in myelinated and unmyelinated fibres [Thornalley, 2002] . Tubulin glycation profoundly inhibits GTP-dependent tubulin polymerization, thus imparing axonal transport [Williams et al. 1982; Cullum et al. 1991] . Excessive glycation of both peripheral and central nervous system myelin components has also been observed in diabetic rats [Vlassara et al. 1983 ]. An interaction between AGE-myelin and macrophages may initiate or contribute to the segmental demyelination associated with diabetic neuropathy [Vlassara et al. 1984] .
Aminoguanidine treatment inhibits an accumulation of fluorescent AGEs in diabetic nerves, and partially prevents demyelination and axonal atrophy probably through the correction of endoneurial microcirculation [Yagihashi et al. 1992] . Recently, Wada et al. reported that OPB-9195 treatment improved tibial motor nerve conduction velocity and restored the decrease in sciatic nerve Na + -K + -ATPase activity in diabetic rats, which was in parallel with suppression of oxidative stress-induced DNA damage [Wada et al. 2001] . ROS production induced by AGE-RAGE interactions might be involved in endoneurial vascular dysfunction and nerve injury in diabetic neuropathy [Greene et al. 1999] .
(ii). Involvement of PKC Na + -K + -ATPase, an intergral component of sodium pump, is involved in the maintenance of cellular integrity and nerve functions [Greene et al. 1987] . The decrease in Na + -K + -ATPase activity is generally observed in neuronal tissues of diabetic patients, which is associated with decrease of myoinositol uptake into nerve and subsequent impairment of nerve conduction [MacGregor et al. 1986] . LY333531 treatment restores the decrease in sciatic nerve and superior cervical ganglion blood flow, motor nerve conduction velocity, coefficient of variation of R-R interval in streptozotocin-induced diabetic rats [Cotter et al. 2002; Nakamura et al. 1999] . These observations suggest that PKC inhibition may have a beneficial effect in preventing the development of diabetic nerve dysfunction, and that this effect may be mediated through its action on the endoneurial microvasculature. However, the role of PKC in hyperglycemia-induced inhibition of Na + -K + -ATPase activity remains controversial.
(iii). Involvement of the Polyol Pathway
Increases in the polyol pathway under diabetes have been long considered to be an important in diabetic neuropathy. The original suggestion is that the polyol pathway-associted sorbitol accumulation could cause osmotic damage to nerves, but there is no definite histological evidence of this, either from animal or human diabetic nerves. Although sorbitol and fructose accumulations in diabetic nerves are accompanied by a decrease in the concentration of another myoinositol, reductions in nerve myoinositol concentrations in human diabetes have not been convincingly demonstrated [Hale et al. 1987] . Recent reports from several clinical trials of AR inhibitors seem to be disappointing. They showed relatively modest improvements in nerve function and morphometry [Efanova, 1999] .
CONCLUSION
In the DCCT-Epidemiology of Diabetes Interventions and Complications Research, the reduction in the risk of progressive retinopathy and nephropathy resulting from intensive therapy in patients with type 1 diabetes persisted for at least four years, despite increasing hyperglycemia [DCCT-EDIC Group, 2000 . Intensive therapy during the DCCT resulted in decreased progression of intima-media thickness six years after the end of the trial as well [Nathan et al. 2003 ]. These clinical studies strongly suggest that socalled 'hyperglycemic memory' causes chronic abnormalities in diabetic vessels that are not easily reversed, even by subsequent, relatively good control of blood glucose. Among the various hypotheses implicated in the pathogenesis of diabetic vascular complications, AGE hypothesis seems to be most compatible with this theory. Further large clinical investigations will be needed to confirm whether blockade of AGE-signaling pathway prevent the development and progression of vascular complications in diabetes. Unless the specific treatment that targets diabetic vascular complications has been developed, multifactorial intensified intervention will be a promising therapeutic strategy for treatment of patients with diabetic vascular complications. 
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